Drug Profile
HIV gp120 vaccine - Merck/Repligen
Alternative Names: RP 135; RP 400cLatest Information Update: 09 Jul 2001
Price :
$50
*
At a glance
- Originator Repligen
- Developer Merck & Co; Repligen
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 12 Jan 2000 New profile, split from generic HIV gp120 vaccine profile